Serina Therapeutics, Inc. (NASDAQ: SER) saw significant insider movement as Chief Scientific Officer Randall Moreadith executed a share sale totaling 4,000 common stock shares on January 20 and 21, 2026. The sale prices ranged between $3.00 and $3.07 per share, culminating in aggregate proceeds of $12,140.
Concurrently, Moreadith also exercised options to purchase an additional 4,000 shares at an exercise price of $0.06 each, amounting to a total outlay of $240. This dual transaction highlights a strategic repositioning of his holdings during this period.
In a related development, Serina Therapeutics received formal notification from the New York Stock Exchange (NYSE) indicating that it no longer meets the requisite criteria for continued listing. The NYSE American segment pinpointed the company's shortfall due to a stockholders' equity figure of $1.6 million as of the fiscal quarter ending September 30, 2025. Further concerns arise from the company's financial trajectory, marked by losses in three of the four most recent fiscal years ending December 31, 2024.
Separately, the company conducted its 2025 Annual Meeting of Stockholders during which investors voted to install two new members to the board of directors: Steve Ledger and Karen J. Wilson. Both will serve terms extending through the 2028 Annual Meeting or until their successors are duly appointed. Voting results were closely contested, with Ledger securing 4,165,885 votes in favor, and Wilson slightly ahead with 4,169,893 affirmative votes. Notably, each nominee also registered 2,681,141 broker non-votes.
These developments paint a complex picture for Serina Therapeutics as it navigates executive insider sales, regulatory compliance challenges, and governance transitions.